368 related articles for article (PubMed ID: 29340807)
1. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
[TBL] [Abstract][Full Text] [Related]
2. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
[TBL] [Abstract][Full Text] [Related]
3. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
4. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
[TBL] [Abstract][Full Text] [Related]
5. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?
Veisman I; Yablecovitch D; Kopylov U; Eliakim R; Ben-Horin S; Ungar B
Isr Med Assoc J; 2021 Dec; 23(12):788-793. PubMed ID: 34954918
[TBL] [Abstract][Full Text] [Related]
7. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
[TBL] [Abstract][Full Text] [Related]
8. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
Vande Casteele N; Khanna R; Levesque BG; Stitt L; Zou GY; Singh S; Lockton S; Hauenstein S; Ohrmund L; Greenberg GR; Rutgeerts PJ; Gils A; Sandborn WJ; Vermeire S; Feagan BG
Gut; 2015 Oct; 64(10):1539-45. PubMed ID: 25336114
[TBL] [Abstract][Full Text] [Related]
9. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA
J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555
[TBL] [Abstract][Full Text] [Related]
10. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.
Ungar B; Haj-Natour O; Kopylov U; Yavzori M; Fudim E; Picard O; Loebstein R; Lahat A; Maor Y; Avidan B; Lang A; Weiss B; Chowers Y; Eliakim R; Ben-Horin S
Medicine (Baltimore); 2015 May; 94(18):e673. PubMed ID: 25950682
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease.
Jagt JZ; Holleman KW; Benninga MA; Van Limbergen JE; de Boer NKH; de Meij TGJ
J Pediatr Gastroenterol Nutr; 2024 Jan; 78(1):57-67. PubMed ID: 38291692
[TBL] [Abstract][Full Text] [Related]
12. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.
Dave MB; Dherai AJ; Desai DC; Keny BG; Shetty DN; Kulkarni S; Peddy K; Ashavaid TF
Indian J Gastroenterol; 2020 Oct; 39(5):426-434. PubMed ID: 33118097
[TBL] [Abstract][Full Text] [Related]
14. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL
Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253
[TBL] [Abstract][Full Text] [Related]
15. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
Hammoudi N; Hassid D; Bonnet J; Tran Minh ML; Baudry C; Vauthier A; Chedouba L; Houzé P; Lourenco N; Aparicio T; Gornet JM; Allez M
Scand J Gastroenterol; 2024 May; 59(5):553-560. PubMed ID: 38353236
[TBL] [Abstract][Full Text] [Related]
16. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
Dreesen E; Van Stappen T; Ballet V; Peeters M; Compernolle G; Tops S; Van Steen K; Van Assche G; Ferrante M; Vermeire S; Gils A
Aliment Pharmacol Ther; 2018 Feb; 47(3):346-355. PubMed ID: 29226370
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
Battat R; Lukin D; Scherl EJ; Pola S; Kumar A; Okada L; Yang L; Jain A; Siegel CA
Inflamm Bowel Dis; 2021 Aug; 27(9):1443-1451. PubMed ID: 33252119
[TBL] [Abstract][Full Text] [Related]
19. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
